FDA Publishes Responses to Good Clinical Practice Inquiries

August 22, 2022

FDA Publishes Responses to Good Clinical Practice Inquiries: FDA oversees clinical trials to ensure they are designed, conducted, analyzed and reported according to federal law and FDA’s regulations. The agency’s oversight of clinical trials protects the rights, safety, and welfare of people participating in clinical trials, and supports the development of safe and effective medical products. The agency addresses inquiries related to good clinical practice and human subject protection policies on an ongoing basis. The downloadable spreadsheet below includes inquiries that have been submitted to the FDA as well as the agency’s replies to each inquiry and is searchable by different fields such as topic, date, etc.

Good clinical practice inquiries and responses 2017 - 2021

See the FDA archive  for inquiries for inquiries prior to 2017. Contact gcpquestions@fda.hhs.gov with questions.

TAGS:

January 6, 2016

Obtaining IND-Related Feedback from FDA

What to do if you experience delays in obtaining IND-related feedback from the FDA: In December 2015, the FDA released a draft guidance, which provides IND sponsors with a number of recommendations...

Large pile of documents and files on an office desk

FDA's "Radical Transparency" Shift: What Regulatory Pros Need to Know

A New Era of FDA Disclosure On Thursday, July 10, 2025, FDA published more than 200 decision letters, known as complete response letters (CRLs). The CRLs were issued in response to applications...

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

Why Sponsors Should Pressure-Test Their IND Before Submission For many sponsors, the Investigational New Drug (IND) application is viewed as a procedural milestone, the point at which a development...